Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The impact of formulary replacement of sildenafil by vardenafil at a local VA hospital

International Journal of Impotence Research volume 20, pages 188–191 (2008)Cite this article

Abstract

The National Veterans Administration (VA) changed its formulary agent for the treatment of erectile dysfunction from sildenafil to vardenafil in January 2006 for economic reasons. The objective of this study was to assess the impact of this formulary change on the patients at a local VA hospital. All non-formulary requests for sildenafil between January 2006 and September 2006 were reviewed. A total of 169 non-formulary requests were made for sildenafil while 7657 patients filled vardenafil prescriptions. Overall, the formulary change from sildenafil to vardenafil appeared to be well tolerated by the vast majority of patients at this local VA hospital. The substantial cost savings to the VA seem to be justified by the minimal adverse effects on men treated for erectile dysfunction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Wright PJ . Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006; 60: 967–975.

    Article  CAS  Google Scholar 

  2. Doggrell SA . Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother 2005; 6: 75–84.

    Article  CAS  Google Scholar 

  3. Mulhall JP, Montorsi F . Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. Eur Urol 2006; 49: 30–37.

    Article  CAS  Google Scholar 

  4. Chair, VHA Medical Advisory Panel and Chief Consultant Pharmacy Benefits Management-Strategic Healthcare Group. National Contract Award for the phosphodiesterase type 5 inhibitors. Department of veterans affairs, memorandum, January 12, 2006. http://www.pbm.va.gov/tig/VardenafilProviderMemo.pdf.

  5. Wessells H, Joyce GF, Wise M, Wilt TJ . Erectile dysfunction. J Urol 2006; 177: 1675–1681.

    Article  Google Scholar 

  6. Pharmacy Benefits Management Strategic Healthcare Group. Drug pharmaceutical prices. http://www.pbm.va.gov/DrugPharmaceuticalPrices.aspx.

  7. VHA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. Criteria-for-use checklist vardenafil non-responders. http://www.pbm.va.gov/criteria/Vardenafil%20Non-Responders.pdf.

  8. VA Research Development. Privacy and confidentiality: memoranda, directives and policies. http://www.research.va.gov/resources/data-security/policies_privacy.cfm.

  9. Moore RA, Derry S, McQuay HJ . Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. BMC Urol 2005; 5: 18.

    Article  Google Scholar 

  10. Berner MM, Kriston L, Harms A . Efficacy of PDE-5 inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the international index of erectile function in broad-spectrum populations. Int J Impot Res 2006; 18: 229–235.

    Article  CAS  Google Scholar 

  11. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I, Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 2006; 3: 1037–1049.

    Article  CAS  Google Scholar 

  12. Stroberg P, Murphy A, Costigan T . Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 2003; 25: 2724–2737.

    Article  Google Scholar 

  13. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005; 96: 1323–1332.

    Article  CAS  Google Scholar 

  14. Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P, Ahuja S . A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment of erectile dysfunction. Clin Ther 2003; 25: 2709–2723.

    Article  CAS  Google Scholar 

  15. von Kietz A, Rajfer J, Segal S, Murphy A, Denne J, Costigan T et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499–507.

    Article  Google Scholar 

  16. Tolra JR, Campana JM, Ciutat LF, Miranda EF . Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006; 3: 901–909.

    Article  CAS  Google Scholar 

  17. Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH et al. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. BJU Int 2007; 99: 376–382.

    Article  CAS  Google Scholar 

  18. Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D . Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005; 2: 848–855.

    Article  CAS  Google Scholar 

  19. Kell PD, Hvidsten K, Morant SV, Harnett JP, Bridge S . Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int 2007; 99: 860–863.

    Article  Google Scholar 

  20. Harnett JP, McLaughlin TP, Mulhall JP, Russell D, McLean S . The economic effect of switching from sildenafil to another phosphodiesterase type 5 inhibitor. Manag Care Interface 2006; 19: 22–26.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    M Singh & A D Seftel

Authors
  1. M Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A D Seftel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Singh.

Additional information

Source of funding: none

Disclosures for M Singh: none. Disclosures for A Seftel: Pfizer, consultant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Singh, M., Seftel, A. The impact of formulary replacement of sildenafil by vardenafil at a local VA hospital. Int J Impot Res 20, 188–191 (2008). https://doi.org/10.1038/sj.ijir.3901606

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901606

Keywords

Search

Advanced search

Quick links